These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25440006)

  • 21. High affinity α3β4 nicotinic acetylcholine receptor ligands AT-1001 and AT-1012 attenuate cocaine-induced conditioned place preference and behavioral sensitization in mice.
    Khroyan TV; Yasuda D; Toll L; Polgar WE; Zaveri NT
    Biochem Pharmacol; 2015 Oct; 97(4):531-541. PubMed ID: 26256075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
    Smith JW; Mogg A; Tafi E; Peacey E; Pullar IA; Szekeres P; Tricklebank M
    Psychopharmacology (Berl); 2007 Feb; 190(2):157-70. PubMed ID: 17115136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A behavioral economic analysis of the value-enhancing effects of nicotine and varenicline and the role of nicotinic acetylcholine receptors in male and female rats.
    Barrett ST; Geary TN; Steiner AN; Bevins RA
    Behav Pharmacol; 2018 Sep; 29(6):493-502. PubMed ID: 29634495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
    Steensland P; Simms JA; Holgate J; Richards JK; Bartlett SE
    Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12518-23. PubMed ID: 17626178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.
    Carroll FI; Navarro HA; Mascarella SW; Castro AH; Luetje CW; Wageman CR; Marks MJ; Jackson A; Damaj MI
    ACS Chem Neurosci; 2015 Jun; 6(6):920-6. PubMed ID: 25891987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.
    Hussmann GP; Turner JR; Lomazzo E; Venkatesh R; Cousins V; Xiao Y; Yasuda RP; Wolfe BB; Perry DC; Rezvani AH; Levin ED; Blendy JA; Kellar KJ
    J Pharmacol Exp Ther; 2012 Nov; 343(2):441-50. PubMed ID: 22899752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
    Spiller K; Xi ZX; Li X; Ashby CR; Callahan PM; Tehim A; Gardner EL
    Neuropharmacology; 2009 Jul; 57(1):60-6. PubMed ID: 19393252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
    Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
    J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
    Bordia T; Hrachova M; Chin M; McIntosh JM; Quik M
    J Pharmacol Exp Ther; 2012 Aug; 342(2):327-34. PubMed ID: 22550286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nicotine + alcohol interoceptive drug state: contribution of the components and effects of varenicline in rats.
    Randall PA; Cannady R; Besheer J
    Psychopharmacology (Berl); 2016 Aug; 233(15-16):3061-74. PubMed ID: 27334469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.
    Marks MJ; O'Neill HC; Wynalda-Camozzi KM; Ortiz NC; Simmons EE; Short CA; Butt CM; McIntosh JM; Grady SR
    Neuropharmacology; 2015 Dec; 99():142-55. PubMed ID: 26192545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.
    Withey SL; Doyle MR; Bergman J; Desai RI
    J Pharmacol Exp Ther; 2018 Aug; 366(2):397-409. PubMed ID: 29784663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse.
    Jackson KJ; Sanjakdar SS; Muldoon PP; McIntosh JM; Damaj MI
    Neuropharmacology; 2013 Jul; 70():228-35. PubMed ID: 23416040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.
    O'Connor EC; Parker D; Rollema H; Mead AN
    Psychopharmacology (Berl); 2010 Feb; 208(3):365-76. PubMed ID: 19967529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor protection studies comparing recombinant and native nicotinic receptors: Evidence for a subpopulation of mecamylamine-sensitive native alpha3beta4* nicotinic receptors.
    Free RB; Kaser DJ; Boyd RT; McKay DB
    Neurosci Lett; 2006 Jan; 392(1-2):135-9. PubMed ID: 16198480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
    Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
    Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline.
    de Moura FB; McMahon LR
    Behav Pharmacol; 2019 Aug; 30(5):412-421. PubMed ID: 30398980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nicotinic receptor antagonists as treatments for nicotine abuse.
    Crooks PA; Bardo MT; Dwoskin LP
    Adv Pharmacol; 2014; 69():513-51. PubMed ID: 24484986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Varenicline provokes impulsive action by stimulating α4β2 nicotinic acetylcholine receptors in the infralimbic cortex in a nicotine exposure status-dependent manner.
    Ohmura Y; Sasamori H; Tsutsui-Kimura I; Izumi T; Yoshida T; Yoshioka M
    Pharmacol Biochem Behav; 2017 Mar; 154():1-10. PubMed ID: 28087221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats.
    Bito-Onon JJ; Simms JA; Chatterjee S; Holgate J; Bartlett SE
    Addict Biol; 2011 Jul; 16(3):440-9. PubMed ID: 21392178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.